Continuous Mobility and Physical Activity in Vertebroplasty vs Sham for Osteoporotic Vertebral Fracture (VOPE2 COMPAS)

June 19, 2025 updated by: Spine Centre of Southern Denmark

Continuous Mobility and Physical Activity in Vertebroplasty vs Sham for Osteoporotic Vertebral Fracture: a Single-center, Double-blind Randomized Controlled Clinical Trial

The aim of this clinical trial is to determine if vertebroplasty is an effective treatment for acute, painful vertebral fractures due to osteoporosis.

The focus of the study is on the physical activity and mobility of participants.

The main questions the trial aims to answer are:

  • Does vertebroplasty lead to increased physical activity as measured by accelerometer?
  • Does vertebroplasty lead to increased mobility as measured by GPS (global positioning system)?
  • Do physical activity and mobility correlate with pain, disability and quality of life?

Researchers will compare vertebroplasty to sham (simulated surgery without active intervention) to understand if vertebroplasty improves physical activity and mobility.

Participants will

  • Undergo vertebroplasty or sham procedure
  • Wear an accelerometer and a GPS-reciever in a belt for 1 week before to 4 weeks after the surgery
  • Answer questionnaires regarding pain, disability and quality of life at regular intervals.

The knowledge gained from this can help determine who would benefit from vertebroplasty.

Study Overview

Detailed Description

Despite attempts at prevention, osteoporotic vertebral fracture occurs with increasing frequency as lifespans increase.

Patients with this disease can experience severe pain and disability, and when conservative treatment is inadequate, vertebroplasty is an option.

In this surgical procedure, polymethyl metacrylate, or "bone cement" is injected into the fractured vertebral body. However, the procedure is currently controversial for the treatment of osteoporotic vertebral fractures because there is not yet consensus on the efficacy.

By investigating the effect of vertebroplasty on mobility and physical activity, this study aims to contribute to resolution of the controversy.

The study is a prospective, double-blind, randomized, sham-controlled clinical trial, where participants will be randomized to either vertebroplasty or a sham operation.

The study is embedded in the ongoing trial "Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy (VOPE2)" with ClinicalTrials.gov ID NCT06141187.

A subset of the participants in VOPE2 will, in addition to previously planned activities, be equipped with wearable accelerometers and a global positioning system (GPS).

The trial is designed in accordance with the SPIRIT guidelines.

Potential participants will be identified by referral to the Center for Spine Surgery and Research from general practitioners, chiropractor, physiotherapist, or from hospital inpatient and emergency departments in the region of Southern Denmark.

Participants will then be examined in an outpatient clinic by a spine surgeon, and have MRI scans and X-ray images analyzed by experienced neuro-radiologists.

If eligible, they will be offered to participate following informed consent. An accelerometer and GPS-reciever attached to an elastic waist band are initiated following inclusion.

Subjects will initially be stratified into two groups based on the number of OVCFs into 1-2 levels or 3-4 levels.

Within each of these two groups, randomization sheets in varying blocks of 8 with an equal number of PVP and sham patients in each block will be generated using software (www.randomizer.org) and will be placed in numbered, opaque, sealed envelopes.

Treatment group assignment is 1:1 and will be performed by a scrub nurse in the surgical theatre after the patient is draped but prior to skin incision.

Throughout the trial, only the surgeon and the OR-nurse will have knowledge of the treatment assignment.

The patient and all assessors remain blinded to the treatment group throughout the study. Spine surgeons who are experienced in PVP will perform the surgical procedures.

Anaesthesiologists and spine surgeons are present at the facility in case of complications, following recommendations by the National Health Authority and have the capacity/capability to decompress the spinal canal in case of cement leakage

Based on qualitative studies and clinical experience, patients with painful osteoporotic vertebral fractures restrict their movement because of pain.

This in turn leads to reduced physical activity and diminished ability to move oneself around and away from home, defined here as mobility.

If vertebroplasty is effective, it is expected to lead to increased physical activity and mobility compared to sham, and the outcomes derived from accelerometers and GPS-recievers can supplement patient reports due to their continuous and objective nature.

Study Type

Interventional

Enrollment (Estimated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients aged 50+ and diagnosed with symptomatic osteoporotic spinal compression fractures between T6 and L5 (incl).
  • Focal tenderness on the level of the vertebral fracture.
  • Fractures verified with oedema of the relevant vertebra on the MRI STIR sequence.
  • Osteoporotic Fractures type 1-4.
  • Fracture involves no more than 4 vertebral body levels.
  • Vertebroplasty can be done in one session.
  • Back pain score measured on a Visual Analog Scale (VAS, 0 to 100) ≥ 60.
  • Able to understand and read Danish.
  • Written informed consent.
  • Relevant pain started ≤ 3 months prior to enrollment.

Exclusion Criteria:

  • Contra-indications for spine surgery.
  • Platelets < 30 mia/l.
  • Osteoporotic Fractures type 5 and Pincer-type.
  • Complete collapse of the vertebral body precluding insertion of needle.
  • Presence of neurologic deficit.
  • Contraindications for MRI scanning.
  • Psychological or psychiatric disorder that is expected to interfere with compliance.
  • Active malignancy.
  • Mini Mental State Examination (MMSE) test score below 24.
  • History of chronic back pain requiring ongoing opiate use.
  • Systemic or local infection of the spine.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Vertebroplasty

Polymethyl-methacrylate (PMMA) cement is prepared and injected slowly into the vertebral body under constant bi-plane fluoroscopy

Interventions:

Procedure: Vertebroplasty

Polymethyl-methacrylate (PMMA) cement is injected slowly into the vertebral body under constant bi-plane fluoroscopy
Other Names:
  • PVP
  • Percutaneous vertebroplasty
Sham Comparator: Sham vertebroplasty

A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.

Interventions:

Procedure: Sham Vertebroplasty

A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in physical activity before and after intervention
Time Frame: One week preoperatively to the end of the fourth postoperative week.

Physical activity is measured by accelerometer and presented as mean ENMO (euclidian norm minus one) and mean TAC/d (total activity count per day).

An unweighted average of valid days within the preoperative week is compared with the unweighted average of valid days within the four postoperative weeks by relative change in percent.

One week preoperatively to the end of the fourth postoperative week.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daily and weekly physical activity
Time Frame: One week preoperatively to 4 weeks postoperatively
Physical activity is measured by accelerometer and presented as difference in mean ENMO (euclidian norm minus one) and mean TAC/d (total activity count per day). Daily means are based on valid wear-time. Weekly means are calculated as unweighted averages of all valid days within the week.
One week preoperatively to 4 weeks postoperatively
Change in daily and weekly physical activity
Time Frame: One week preoperatively to 4 weeks postoperatively

Physical activity is measured by accelerometer and presented as difference in mean ENMO (euclidian norm minus one) and mean TAC/d (total activity count per day). Daily means are based on valid wear-time. Weekly means are calculated as unweighted averages of all valid days within the week.

This outcome supplements the primary outcome to cover changes within the full study period. Changes are reported as relative percentages.

One week preoperatively to 4 weeks postoperatively
Physical activity levels
Time Frame: One week preoperatively to 4 weeks postoperatively
Based on cut-points applied to the ENMO or count measurements, the valid wear-time is divided into intensity classes "sedentary", "light activity" or "moderate to vigorous activity". Time spent in each class is presented as percentage of valid wear-time.
One week preoperatively to 4 weeks postoperatively
Change in physical activity levels
Time Frame: One week preoperatively to 4 weeks postoperatively
Based on cut-points applied to the ENMO or count measurements, the valid wear-time is divided into intensity classes "sedentary", "light activity" or "moderate to vigorous activity". Time spent in each class is presented as percentage of valid wear-time and changes as absolute percentage points.
One week preoperatively to 4 weeks postoperatively
Total daily distance and change in total daily distance
Time Frame: One week preoperatively to 4 weeks postoperatively
Total daily distance traveled in meters based on GPS positions. Changes are relative in percentages.
One week preoperatively to 4 weeks postoperatively
Time spent stationary and change in time spent stationary
Time Frame: One week preoperatively to 4 weeks postoperatively
Percentage of time spent stationary based on GPS positions relative to the days' recording. Change is absolute percentage points.
One week preoperatively to 4 weeks postoperatively
Time spent away from home and change in time spent away from home
Time Frame: One week preoperatively to 4 weeks postoperatively
Percentage of time per day where the GPS records a position away from home relative to the days' recordings. Change is in absolute percentage points.
One week preoperatively to 4 weeks postoperatively
Patient-reported pain intensity.
Time Frame: VAS will be recorded once preoperatively and again 1, 2, 3, 4 and 5 days + 2 and 4 weeks postoperatively.
Pain intensity over the previous 24 hours using the 100-point visual analog scale, where 0 is no pain and 100 is the worst imaginable pain.
VAS will be recorded once preoperatively and again 1, 2, 3, 4 and 5 days + 2 and 4 weeks postoperatively.
Patient-reported disability
Time Frame: Preoperatively and at 4 weeks postoperatively
The patients rate their disability using the Oswestry Disability Index (ODI) questionnaire.
Preoperatively and at 4 weeks postoperatively
Patient-reported health-related quality of life.
Time Frame: Preoperatively and at 4 weeks postoperatively
Health-related quality of life. on the EuroQol 5-dimension 5-level (EQ-5D-5L)
Preoperatively and at 4 weeks postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Mikkel Ø Andersen, Prof, MD, Spine Centre of Southern Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

January 9, 2025

First Submitted That Met QC Criteria

January 9, 2025

First Posted (Actual)

January 15, 2025

Study Record Updates

Last Update Posted (Estimated)

June 25, 2025

Last Update Submitted That Met QC Criteria

June 19, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 23/40938
  • 112199 (Registry Identifier: Den Videnskabsetiske Komité for Region Syddanmark)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data from questionnaires, accelerometers and GPS-records will be made available in an anonymized form to researchers who present a proposal for the use that is reasonable and can be approved by the study authors.

IPD Sharing Time Frame

The IPD and data will be stored for five years from the completetion of the study at the trial site followed by archiving at the Danish National Archives.

IPD Sharing Access Criteria

Researchers can request access to the information by contacting the investigator via email at soren.wittorff.sorensen@rsyd.dk

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoporotic Vertebral Compression Fractures

Clinical Trials on Vertebroplasty

Subscribe